|Day Low/High||112.77 / 114.50|
|52 Wk Low/High||94.59 / 141.86|
The light volume keeps me hesitant, though here are a few recent standout names.
The biotechnology sector has weathered the correction and looks ready to push higher.
Contributor Ken Shreve takes a look at economic data and earnings reports scheduled for the coming week.
The high-fliers I have been showing can reap huge returns, but make sure you can handle the volatility.
The shares are highly likely to test $100. Just keep a trailing stop on any existing positions.
With only one drug on the market, the pharmaceutical company is expanding its pipeline.
News that Greece will need further austerity measures dragged down world markets and U.S. futures.
Stocks were poised for a moderately higher ahead of this highly anticipated monthly event.
Despite the massive upsurge, there are still a few interesting setups to consider here.
It's not that the market action is bad, it just isn't lively enough to support aggressive action.
Some breakouts, like that of Apple lately, cannot be taken at face value -- especially if they lack volume.
EBIX broke out on Tuesday in heavy volume, which hints at institutional buying in this stock.
Consider this strategy to help protect your portfolio as what could be a very treacherous earnings season approaches.
Despite the solid performance so far this year, there's still time to get on board and ride the profit train.
Money is still flowing into some market-moving names, but not into small-caps.
Alexion Pharma is too far above established support to be considered a buy at this point, so wait for a pullback closer to this key level.
If institutional buyers come into these stocks soon, we could have a nice year-end rally on our hands.
Focus on stocks that have come in no more than 30% off their recent highs as they have a good chance of forming sound bases and staging new breakouts.